The Wolverine Stack: BPC-157 + TB-500

The name comes from the research community, not from any pharmaceutical or clinical source. Researchers and enthusiasts use "Wolverine Stack" to describe the pairing of BPC-157 and TB-500 because both peptides are studied for tissue repair and wound healing, and their proposed mechanisms are largely complementary.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in gastric juice. It does not exist in this form naturally. TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in actin regulation and cell motility that is produced naturally in the thymus and many other tissues. Both are research-only compounds with no approved human pharmaceutical applications.

Researchers studying these two compounds together often note that they appear to work through distinct pathways, which is part of the rationale for studying them in combination. The table below summarizes what published research has examined for each.

• Tendon and ligament tissue Both peptides have been studied in rodent models of tendon injury. BPC-157 studies have examined fibroblast activation and collagen remodeling; TB-500 studies have examined actin-mediated cell migration in connective tissue. The research communities overlap considerably here.
• Wound healing and tissue closure TB-500 has a longer published record in wound healing research, including studies on skin incision models. BPC-157 has been studied for its effect on growth factor expression in wound environments. Both compounds appear in the same literature reviews on tissue repair peptides.
• Inflammatory response modulation Animal studies on both compounds have examined effects on pro-inflammatory cytokine expression. The proposed mechanisms differ (BPC-157 acts partly through nitric oxide pathways; TB-500 through thymosin beta-4 fragment activity), but the downstream research question is similar.
• Musculoskeletal recovery Muscle injury models in rodents have been used to study both compounds, particularly in the context of crush injury and ischemic damage. This is the research context that generates the most community interest in the combination.

The evidence base for both compounds is almost entirely preclinical. BPC-157 has been studied extensively in rodent models across a wide range of tissue types, but as of 2025 no peer-reviewed human clinical trials have been published. TB-500 (the synthetic fragment) shares this limitation for most applications, though the full thymosin beta-4 protein has advanced to Phase 3 trial data in the context of dry eye and ocular surface disease.

The "Wolverine Stack" terminology is community-generated and does not appear in peer-reviewed literature. Researchers interested in the combination are typically extrapolating from two separate bodies of preclinical work. Anyone evaluating this combination should read the individual research notes for each compound to understand where the evidence is stronger and where it remains speculative.

Both compounds are sold as lyophilized powder in 5 mg vials by most research vendors. Pricing varies significantly across vendors based on purity certification, batch testing practices, and shipping region. The ranges below reflect typical vendor pricing as of 2025 and should be verified with the price tool.